Nordic Life Science 1
You have your headquarters in Lund, Sweden. What
are the benefits of being located in Medicon Village? “Medicon Village is an inspiring community that is driven by a mission to bring science to life and help society at the same time. Our headquarters in Lund not only pay tribute to the University’s Division of Atom Physics, where our lung monitoring method GASMAS was originally developed, but also the region’s significant role in the history of neonatal care. Following in the footsteps of diagnostic ultrasound, which was developed in Lund in the 1950s, our Lund based medical technology innovation once again has the potential to revolutionize health care the world over. Another benefit of being located near Medicon Village is being part of a community of inspiring female CEOs of medtech and life science companies as a member of SmiLe Incubator. SmiLe is a frontrunner when it comes to female leadership: almost 70 percent of its companies are headed by a female CEO. Of all the IPOs that have taken place so far this year, only 3 of 25 companies have a female CEO. In addition to myself as CEO, GPX Medical’s Chair of the Board and one of the innovators behind our technology, as well as the CTO, are all women.” Where do you see GPX Medical in 5-10 years? “In 5–10 years we hope to have entered the US market and the major markets in Europe and have strong collaboration and partnerships with hospitals and within the medtech industry. We would also have expanded our platform technology beyond the neonatal application. In the short term our goals are to conduct a preclinical study, initiate a clinical pilot study on newborns, and determine a clinical study plan together with our key opinion leaders. In 2021 we also aim to develop NEOLA’s final product functions, conduct a user study with neonatologists and nurses, and recruit a Director of Clinical Affairs.” With NEOLA, GPX Medical aims to upgrade today’s neonatal intensive care How have you handled the changes from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR); has it affected your company and if so, how? “I have a strong and experienced team that knows the drill, having previously worked with developing and commercializing medical technology innovations in Europe. They are closely monitoring the transition from MDD to MDR to ensure that NEOLA’s product development process is executed in accordance with the new guidelines. I have full confidence that with their expertise we will navigate this transition successfully and receive EU regulatory approval in line with our business goals.” NLS 66 NORDICLIFESCIENCE.ORG